Larvol Delta - IMV-Inc-Announces-Initial-Data-from-the-Ongoing-Phase-2B-VITALIZE-Trial-in-Patients-with-rr-DLBCL

maveropepimut-S (MVP-S) - IMV Inc

Keytruda (pembrolizumab) - Merck (MSD)

https://www.businesswire.com/news/home/20221215005319/en/IMV-Inc.-Announces-Initial-Data-from-the-Ongoing-Phase-2B-VITALIZE-Trial-in-Patients-with-rr-DLBCL

Dec 15, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next